Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cerus Corp

CERS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Small Cap Analyst: BUY

Last Close

$2.59

▲ +0.78%

Market Cap $521.95M · Vol 324.38K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$521.95M

Small Cap

Div Yield

N/A

EPS Growth

+45.84%

YoY

RSI (14)

24.32

Momentum

Beta

1.82

vs Market

52W High

$3.47

25.25% below

52W Low

$1.17

121.37% above

Volume

324.38K

Avg 705.06K

P/B

6.16

Price-to-book

ROE

N/A

Return on equity

Free Float

96.50%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cerus Corp (CERS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CERS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.26%

+18.26%

-7.17%

+15.63%

YTD

+25.73%

+94.74%

+48.00%

-60.09%

Financials & Valuation

TTM · Annual

Total Revenue	$233.80M
Net Income	$-15,637,000.00
Revenue Growth (YoY)	+5.28%
Gross Margin	59.86%
Operating Margin	-3.71%
Net Profit Margin	-6.69%
ROE	N/A
ROA · ROIC	-7.23% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.68
P/B	6.16
P/FCF	352.44
EPS Growth	+45.84%
Outstanding Shares	201.52M

Technical Indicators

50-Day SMA	$2.82
200-Day SMA	$2.37
RSI (14)	24.32
Beta	1.82
52-Week High	$3.47
52-Week Low	$1.17

Volume Today	324.38K
Avg Daily Volume (30D)	705.06K
Relative Volume	0.46x
Volatility (10D)	25.02
Volatility (30D)	98.79
Free Float	96.50%

Analyst Consensus

BUY

Current Price $2.59

Mean Target $5.13

52W Low$1.17 52W High$3.47

Current

Target

$1.17 $3.47

Current Analyst target

+97.88% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S97DG4

ISINUS1570851014

CountryUnited States of America

Sub-IndustryMedical Devices & Implants

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

SYK Stryker Corp -1.58% SN-.L Smith & Nephew PLC +1.14% SNN Smith & Nephew PLC +0.63% GKOS Glaukos Corp -1.60% 300896.SZ Imeik Technology Development Co Ltd +2.47%

Company Profile

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.